Actively Recruiting
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Led by Hunan Province Tumor Hospital · Updated on 2024-09-19
70
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
CONDITIONS
Official Title
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Diagnosed with advanced non-squamous non-small cell lung cancer confirmed by histopathology
- Cancer is potentially resectable
- Treatment plan includes crizotinib or standard chemotherapy
You will not qualify if you...
- Contraindication to chemotherapy
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongchang Zhang
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
N
Nong Yang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here